Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
4.560
+0.200 (4.59%)
At close: Mar 4, 2026, 4:00 PM EST
4.650
+0.090 (1.97%)
After-hours: Mar 4, 2026, 6:12 PM EST
Orchestra BioMed Holdings Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Orchestra BioMed Holdings stock have an average target of 14.25, with a low estimate of 10 and a high estimate of 20. The average target predicts an increase of 212.50% from the current stock price of 4.56.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
The average analyst rating for Orchestra BioMed Holdings stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $11 → $12 | Buy | Maintains | $11 → $12 | +163.16% | Jan 9, 2026 |
| TD Cowen | TD Cowen | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +228.95% | Dec 10, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +338.60% | Nov 13, 2025 |
| Barclays | Barclays | Buy Maintains $12 → $11 | Buy | Maintains | $12 → $11 | +141.23% | Nov 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +119.30% | Sep 4, 2025 |
Financial Forecast
Revenue This Year
3.61M
from 2.64M
Increased by 36.66%
Revenue Next Year
3.69M
from 3.61M
Increased by 2.30%
EPS This Year
-1.78
from -1.66
EPS Next Year
-1.63
from -1.78
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 4.2M | 4.8M | ||||
| Avg | 3.6M | 3.7M | ||||
| Low | 3.1M | 2.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 59.2% | 34.0% | ||||
| Avg | 36.7% | 2.3% | ||||
| Low | 18.9% | -26.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.82 | -1.52 | ||||
| Avg | -1.78 | -1.63 | ||||
| Low | -1.74 | -1.76 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.